ArticleNorthern clinics of Istanbul2026
Impact of body mass index on progression-free survival and endocrine immune-related adverse events in advanced NSCLC patients treated with nivolumab: A retrospective cohort study.
Article in Northern clinics of Istanbul, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveBody mass index (BMI) is a well-established prognostic factor in many cancer types. While BMI has been paradoxically associated with improved outcomes under immune checkpoint inhibitors (ICIs), its role in toxicity risk remains underexplored. This study examines the relationship between BMI and both progression-free survival (PFS) and immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer (NSCLC) receiving second-line treatment with nivolumab.
methodsThis retrospective study examined 305 patients with histologically confirmed stage IV NSCLC who experienced progression after platinum-based chemotherapy. Patients were grouped based on whether their BMI was above or below the median value of 24.8 kg/m
resultsNo statistically significant difference in PFS was observed between BMI groups (<24.8: 7.53 months vs. ≥24.8: 8.30 months, p>0.05). Endocrine irAEs, however, occurred more frequently in patients with a higher BMI (p=0.034). No significant associations were found between BMI and hematologic (p=0.637), hepatic, gastrointestinal, or pulmonary irAEs. BMI was not predictive of PFS but was associated with endocrine toxicity.
conclusionThese findings suggest that BMI may serve as a simple indicator for toxicity risk stratification in immunotherapy settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.